Literature DB >> 18299377

Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia.

T-Y Hung1, V-K Seow, C-F Chong, T-L Wang, C-C Chen.   

Abstract

Gabapentin toxicity should be considered one of the differential diagnoses of altered consciousness in patients with compromised renal function even after a single dose. We report a 57-year-old woman with diabetes mellitus and uraemia on regular haemodialysis who developed severe dizziness and lethargy after a single recommended dose of gabapentin for bilateral leg dysthesia. Because of progressive drowsiness and decreasing level of consciousness, one session of haemodialysis was performed and clinical recovery was dramatic. The adverse effects of gabapentin seem to vary from person to person and should be viewed with a high degree of suspicion, especially in patients taking this drug at the beginning.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299377     DOI: 10.1136/emj.2007.053470

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  4 in total

1.  Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.

Authors:  Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen
Journal:  J Am Soc Nephrol       Date:  2018-06-05       Impact factor: 10.121

Review 2.  Neuropsychiatric complications of chronic kidney disease.

Authors:  Rory McQuillan; Sarbjit V Jassal
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

Review 3.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

4.  Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy.

Authors:  A K Guddati; Z Zafar; J T Cheng; S Mohan
Journal:  Indian J Nephrol       Date:  2012-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.